Published in PLoS One on December 04, 2009
NK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRs. PLoS One (2010) 1.59
Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood (2010) 1.32
The tumor microenvironment: a pitch for multiple players. Front Oncol (2013) 1.07
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med (2013) 1.02
Impact of brief exercise on peripheral blood NK cell gene and microRNA expression in young adults. J Appl Physiol (1985) (2013) 0.91
Inositol phospholipid signaling and the biology of natural killer cells. J Innate Immun (2011) 0.89
A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation. Oncotarget (2015) 0.80
KIR gene variability in cutaneous malignant melanoma: influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis. Immunogenetics (2013) 0.78
MHC class I chain-related gene a diversity in patients with cutaneous malignant melanoma from southeastern Spain. Dis Markers (2015) 0.76
Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology (2015) 0.75
Biology of natural killer cells. Adv Immunol (1989) 14.77
NK cell recognition. Annu Rev Immunol (2005) 14.40
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods (2003) 11.81
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 11.04
Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature (2005) 7.40
Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol (2001) 7.07
Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 6.73
ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity (2001) 5.42
Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol (1996) 4.24
Regulation of immune responses through inhibitory receptors. Annu Rev Immunol (1999) 4.06
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 3.52
Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol (2001) 2.38
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity (2007) 2.20
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol (2002) 1.39
Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol (2009) 1.37
Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev (2006) 1.34
Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer (2006) 1.32
Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. Immunol Rev (1997) 1.29
Analysis of HLA-E expression in human tumors. Immunogenetics (2003) 1.23
Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol (2006) 1.20
Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc Natl Acad Sci U S A (1997) 1.15
The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. Eur J Immunol (1998) 0.92
Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Res (2004) 0.90
Mesenchymal stem cells in health and disease. Nat Rev Immunol (2008) 11.14
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 4.32
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci U S A (2007) 3.60
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 3.52
Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood (2007) 3.38
The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med (2009) 3.17
Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J (2003) 3.06
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol (2007) 2.97
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A (2005) 2.80
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood (2009) 2.75
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 2.71
Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A (2004) 2.66
The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol (2004) 2.64
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol (2002) 2.57
Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A (2005) 2.55
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res (2012) 2.54
Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A (2003) 2.51
Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol (2007) 2.50
Immunoregulatory function of mesenchymal stem cells. Eur J Immunol (2006) 2.47
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 2.44
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol (2011) 2.44
NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood (2005) 2.31
The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol (2003) 2.29
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A (2004) 2.23
Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood (2002) 2.21
North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord (2010) 2.14
What is a natural killer cell? Nat Immunol (2002) 2.11
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol (2002) 2.02
The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood (2007) 1.99
DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med (2004) 1.96
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood (2004) 1.95
Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A (2004) 1.95
A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood (2012) 1.92
Surface NK receptors and their ligands on tumor cells. Semin Immunol (2006) 1.92
Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res (2004) 1.87
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol (2007) 1.86
Cellular ligands of activating NK receptors. Trends Immunol (2005) 1.84
Killer immunoglobulin-like receptors. Curr Opin Immunol (2004) 1.83
The three-dimensional structure of the human NK cell receptor NKp44, a triggering partner in natural cytotoxicity. Structure (2003) 1.82
Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood (2011) 1.78
NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J Immunol (2007) 1.78
Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood (2010) 1.75
Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A (2010) 1.74
Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. J Exp Med (2006) 1.72
Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev (2006) 1.71
miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J Neurooncol (2009) 1.68
A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood (2010) 1.67